Physician profile
Kathleen Stapleton
NPI 1174757397
$2,312.88
in general payments reported to CMS, 2019-2025
17 companies · $919 in 2025
The $919 reported for 2025 was more than what 83% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $294 · 2024: $1,100 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $413.86 | 2024-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $315.05 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $268.35 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $260.74 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $202.93 | 2024-2025 | Airsupra, Farxiga |
| Dexcom, INC. | $149.90 | 2024-2025 | Dexcom G6 Transmitter |
| Renalytix Ai, INC. | $146.15 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Amgen INC. | $129.28 | 2023-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $123.12 | 2023-2025 | |
| Astellas Pharma US INC | $85.64 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $73.15 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.49 | 2024 | Jardiance |
| Sanofi Pasteur INC. | $27.63 | 2025 | |
| Exact Sciences Corporation | $26.04 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $21.60 | 2023 | Belsomra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21.39 | 2025 | Voquezna |
| Vertex Pharmaceuticals Incorporated | $13.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Stapleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.